Drug recall · January 26, 2022
Semglee recall
Why: Labeling: Missing Label: label missing from some Semglee prefilled pens.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.
- Lots / codes
Batch # BF20003118, Exp. August 2022
- Quantity
- 73,175 prefilled pens
- Company
- Mylan Pharmaceuticals Inc, Morgantown, WV
- Distribution
- Nationwide in the USA and Thailand.
- Initiated
- January 5, 2022 · Voluntary: Firm initiated
- Classified
- January 28, 2022
- Reported
- January 26, 2022
- Ended
- January 12, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Insulin glargine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.